U.S. Neurostimulation Devices Market

Millions of people in the United States (U.S.) experience some degree of neurological impairment over the course of a lifetime.  Although many people remain asymptomatic or are able to tolerate the minor symptoms that may occur, manyothers seek treatment for debilitating symptoms that affect daily functioning and quality of life. Typically, the initial treatment option for neurological disorders suchas chronic pain, hearing loss, and sleep apnea is standard medical (drug) therapy or surgery; however, neurostimulation is gaining in popularity as a viable alternative among many people in the U.S. and worldwide.

Implantable neurostimulation systems available in the U.S. market may betemporary or permanent (depending on its indication) and typically consist of three implantable and two external components, with the implantable extension connecting the lead to the power source, and the lead used to deliver electrical stimulation to targeted nerve(s).

Implant procedures are minimally invasive, reversible, and have demonstrated substantial success in carefully selected patient populations. Neurostimulationsystems are expected to achieve greater acceptance over the next decade as theyare demonstrated to provide relief to no-option patients who are refractory to drug or other conservative treatment.  Among the major risks associated with neurostimulation implants are the possibility of device-related erosion, infection, or migration as well as sudden interruptions in therapy due to electrical or mechanical problems, and abnormal stimulation due to a damaged device; concomitant muscle stimulation, hematoma, implant site inflammation/pain, seizures,and electromagnetic interference also may occur. Despite these risks, however, neurostimulation may offer the only viable choice for selected patients with debilitating conditions, and often results in fewer side effects compared with the use of drug therapy.